Skip to content
2000
Volume 8, Issue 2
  • ISSN: 1874-4710
  • E-ISSN: 1874-4729

Abstract

This review mainly focuses on the dosimetry methodology which includes consideration of the number and time points of scans, imaging methodology, methods for integrating time-activity curves and calculating absorbed doses. 177Lu-labelled compounds show many advantages for dosimetry assessments due to attractive physical properties which comprise low abundance of photons for sufficient post-therapy imaging, a clearly separated gamma peak at 208 keV, and a low range of beta particles. The most up-to-date results of absorbed dose calculations for the kidneys, bone marrow, and tumors are provided. The absorbed doses reported for radiopeptide therapies using 177Lu labelled compounds taken from clinical studies show a high variability, presumably because of the different applied methodologies.

Loading

Article metrics loading...

/content/journals/crp/10.2174/1874471008666150313104212
2015-08-01
2025-06-13
Loading full text...

Full text loading...

/content/journals/crp/10.2174/1874471008666150313104212
Loading

  • Article Type:
    Research Article
Keyword(s): 177Lu; dosimetry; molecular radiotherapy; radiopeptide therapy
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test